Articles By Anuja Singh
Can hellocare.ai and Epic’s Native Integration Redefine AI-Driven Inpatient Care Across US Hospitals?
Key Takeaways Epic Integration Enhances Bedside Engagementhellocare.ai’s purpose-built virtual care device now supports Epic MyChart Bedside TV out…
By
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape Chronic Disease Care in China’s Digital…
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in…
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era…
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal…
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Can hellocare.ai and Epic’s Native Integration Redefine AI-Driven Inpatient Care Across US Hospitals?
Key Takeaways Epic Integration Enhances Bedside Engagementhellocare.ai’s purpose-built virtual care device now supports Epic MyChart Bedside TV out…
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape Chronic Disease Care in China’s Digital…
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in…
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era…
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal…
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…